3SBio's oncology segment is dedicated to the research, development, and commercialization of innovative therapies for various cancer types. This segment focuses on developing targeted therapies, immunotherapies, and supportive care products to improve patient outcomes and quality of life. Key products include Cipterbin, used in combination with chemotherapy for HER2-positive metastatic breast cancer, and SSGJ-707, a PD-1/VEGF bispecific antibody in Phase II clinical trials. The company collaborates with partners like Pfizer to expand the global reach of its oncology pipeline. Future opportunities include exploring novel drug targets, personalized medicine approaches, and combination therapies to address unmet needs in cancer treatment.

The nephrology segment at 3SBio focuses on developing and providing treatments for kidney-related diseases. This includes products like Xenopax, used to prevent acute rejection after renal transplant, and Sparin, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. The company is committed to improving the lives of patients with renal disorders through innovative therapies and comprehensive disease management strategies. Future growth potential lies in developing novel treatments for chronic kidney disease, dialysis-related complications, and other unmet needs in nephrology.

3SBio's hematology segment is focused on developing and commercializing biopharmaceutical products for the treatment of blood disorders. Key products include TPIAO, a recombinant human thrombopoietin used to treat chemotherapy-induced thrombopenia and immune thrombocytopenia, and EPIAO and SEPO recombinant human erythropoietins to treat anemia. The company is dedicated to improving the lives of patients with hematological conditions through innovative therapies and comprehensive disease management strategies. Future opportunities include developing novel treatments for anemia, thrombocytopenia, and other blood disorders, as well as exploring gene therapy and cell therapy approaches.